Additionally, for TRPV4 mutation-induced OA chondrodysplasia, the TRPV4 activators GSK1016790A or 4α-PDD have shown therapeutic efficacy (Clark et al., 2010). The gene discussed is TRPV4; the disease is chondrodysplasia.